Literature DB >> 2412064

Serotonin and the heart: effects of ketanserin on myocardial function, heart rate, and arrhythmias.

S Saman, F Thandroyen, L H Opie.   

Abstract

Serotonergic receptors have been identified in the blood vessels of the heart and in myocardial tissue. We indirectly examined the potential significance of these receptors by studying the properties of ketanserin, an S2-serotonergic antagonist. In an isolated rat heart preparation, ketanserin at 10(-6) M slowed the heart rate, whereas at 10(-5) M it also decreased the cardiac output. Because the stroke volume rose, a negative inotropic effect could be excluded. Electrophysiologically, ketanserin (10(-7) M or more) increased the action potential duration of the superfused guinea-pig papillary muscle preparation. This Class III effect may account for the antiarrhythmic action of ketanserin (5 X 10(-6) M-10(-5) M) in an ischemic-reperfused rat heart preparation. The possibility of nonspecific effects of ketanserin such as an interaction with alpha 1-adrenergic receptors merits careful evaluation, but in the case of the Class III effect, ketanserin was approximately 100 times more active than prazosin in widening the action potential duration. These data suggest that even high concentrations of ketanserin are unlikely to have harmful effects on the myocardium and might, on the contrary, have beneficial effects in the context of myocardial ischemia.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2412064

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  4 in total

1.  Acute electrophysiologic effects of an HT2-serotonin antagonist, ketanserin, in humans.

Authors:  G C Kaye; D Mehta; S Wafa; A J Camm
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

2.  The 5-HT2 antagonist ketanserin is an open channel blocker of human cardiac ether-à-go-go-related gene (hERG) potassium channels.

Authors:  Q Tang; Z-Q Li; W Li; J Guo; H-Y Sun; X-H Zhang; C-P Lau; H-F Tse; S Zhang; G-R Li
Journal:  Br J Pharmacol       Date:  2008-06-23       Impact factor: 8.739

3.  Effect of intravenous ketanserin on the human action potential duration at fixed heart rate.

Authors:  A J Drake-Holland; M I Noble; S Pugh; C Mills
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

4.  The effects of the 5 HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension.

Authors:  D J Stott; A R Saniabadi; J Hosie; G D Lowe; S G Ball
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.